Medicare Part D's $2,000 Drug Cap vs ACA Marketplace Costs: What Losing Medicare Eligibility Under H.R. 1 Means for Your Eliquis and Jardiance Bills in 2027

The deadline you may not know you have

If you or a family member is a lawfully present immigrant currently enrolled in Medicare — a refugee, asylee, or certain visa holder — you need to know this now: under a CMS proposed rule implementing H.R. 1, the reconciliation bill Congress passed last year, thousands of people are scheduled to lose Medicare eligibility starting January 1, 2027. The Medicare Rights Center flagged this directly in its September 2026 comments to CMS, urging the agency to soften the transition. As of today, the agency hasn't.

Here's why this matters for a topic that usually gets framed as a "coverage" question but is really a drug cost math problem: losing Medicare doesn't just mean losing a card. It means losing Part D's $2,000 annual out-of-pocket cap — one of the most valuable, least-understood protections in the entire program — and landing in the ACA marketplace, where drug formularies work completely differently and where, as KFF Health News reported this year, premiums have already been climbing by "hundreds of dollars a month" for people who thought they had this figured out.

Three decisions, three deadlines, if this applies to you or someone you help manage care for:

1. Before your Medicare termination date — confirm whether you have any path to stay enrolled (appeal, re-verification, alternate eligibility category).
2. Within 60 days of losing Medicare — you likely qualify for an ACA Special Enrollment Period. Miss it, and you're waiting for the next open enrollment window with a gap in drug coverage.
3. If you ever regain Medicare eligibility later — you need "creditable coverage" documentation for every month you were off Part D, or you face a late enrollment penalty that compounds for life. This is the part almost nobody explains, and it's irreversible once the penalty clock starts.

What Part D's $2,000 cap is actually protecting you from

Since the Inflation Reduction Act phased in fully, Medicare Part D in 2026 works like this: a deductible of up to $590, then 25% coinsurance on covered drugs, until your total out-of-pocket spending hits $2,000 for the year. After that, you pay $0 for the rest of the year — no matter what your drugs cost at list price. This is the mechanism we've broken down in detail in our formulary tier placement analysis, and it's the single biggest reason Medicare drug coverage outperforms most commercial insurance for people on multiple chronic-condition medications.

The ACA marketplace has no equivalent hard drug cap. It has an overall plan out-of-pocket maximum ($9,200 for an individual in 2026, and expected to rise again for 2027), but that number covers all medical and drug spending combined, and many silver and bronze plans apply separate deductibles and 40%+ coinsurance tiers for specialty drugs before you ever reach it. Two people paying for the exact same prescriptions can land in completely different cost brackets depending on which side of that eligibility line they're on.

A worked example: Eliquis and Jardiance, two coverage systems

Consider someone we'll call Maria — a lawful permanent resident who has been on Medicare for three years, taking Eliquis (apixaban, for atrial fibrillation) and Jardiance (empagliflozin, for type 2 diabetes with heart failure risk). Combined list price for both drugs runs roughly $1,125/month, or about $13,500/year.

Under Medicare Part D in 2026:

• Deductible: $590
• 25% coinsurance until she hits the $2,000 cap
• Standalone PDP premium: based on Toravine's analysis of the cms_medicare_plan_premiums dataset (1,236 plan records), average standalone Part D premiums range from roughly $18 to $98/month depending on state and insurer, so call it $40/month = $480/year
• Total annual cost: about $2,480, regardless of the $13,500 list price

Under an ACA marketplace silver plan, if she loses Medicare eligibility January 1, 2027:

• Separate drug deductible on many plans: $500–$1,500
• Specialty/non-preferred brand coinsurance: commonly 40–50% until the plan's overall out-of-pocket max is reached
• If her plan places either drug in a higher tier (a real possibility — insurers reshuffle formularies every year, which we've documented in detail in our Part D formulary trap coverage), she could realistically hit the $9,200 individual out-of-pocket max on drug costs alone in a bad year
• Add the premium increases KFF Health News documented — households seeing bills climb by hundreds of dollars a month — and her total annual cost could land anywhere between $9,200 and $13,000+, before a single ER visit or specialist copay

That's a swing of $6,700 to $10,500 in a single year, for identical prescriptions, purely because of which side of an eligibility rule she falls on. This is the kind of analysis Toravine runs for you — so you don't have to build the spreadsheet yourself.

Side-by-side: where the money actually goes

Factor	Medicare Part D (2026 structure)	ACA Marketplace Silver Plan
Deductible	Up to $590	$500–$1,500 (drug-specific, varies by plan)
Coinsurance after deductible	25%	30–50% depending on tier
Hard annual drug cost cap	$2,000 (IRA statutory cap)	None — folds into overall plan OOP max
Overall plan OOP max	N/A (drug cap is separate and lower)	~$9,200 individual (2026), rising for 2027
Formulary stability	CMS-regulated tiers, published annually	Insurer-set, can change specialty tier placement without much notice
Premium volatility	Relatively stable, state-by-state variation	Documented "hundreds of dollars a month" increases per KFF reporting

The claims-denial risk you're inheriting, too

There's a second layer here that doesn't show up in a premium comparison. Medicare has a standardized, federally regulated appeals process for coverage denials. The ACA marketplace runs on each insurer's own internal review process — and insurers are currently facing real friction over how they handle denials. Healthcare Dive reported this month that Texas hospitals are suing Independence Blue Cross directly over denied claims, on top of an existing $2.8 billion settlement over separate billing disputes. Separately, a new lawsuit is challenging how Medicaid work requirement programs define "medical frailty" exemptions — another example of coverage rules getting litigated in real time, with beneficiaries caught in the middle while the rules get sorted out.

None of this means ACA coverage is bad insurance. It means that if you're being pushed off Medicare and into the marketplace involuntarily, you're also inheriting a different, less standardized dispute process for when a claim or prior authorization gets denied — at exactly the moment you have the least bandwidth to fight it. You can model this for your specific situation at Toravine, factoring in your actual state, insurer, and drug list.

The Durham parallel: this isn't hypothetical stress

KFF Health News' profile of Joshua and Ashley Durham — two healthcare practitioners in Idaho who understand medical risk better than almost anyone, and who still chose to go uninsured rather than absorb their new premium — is worth sitting with. If people trained in medicine are making that trade-off, the math for someone losing Medicare involuntarily, with less warning and less control over the timing, is even harder. We covered a closely related version of this exact decision — ACA premium spikes colliding with Medicare enrollment timing — in our analysis of ACA premiums vs. the Medicare late enrollment penalty, and the core lesson holds here too: the penalty for guessing wrong on timing doesn't show up immediately. It shows up years later, permanently, added to every future premium.

What to check before your termination date

Based on Toravine's analysis across our combined dataset — census_acs_medicare (6,287 rows), cms_medicare_plan_premiums (1,236 rows), medigap_rates (3,570 rows), and cms_medicare_irmaa (174 rows) — a few things determine whether this transition costs you $2,500 or $12,000:

• Your state. Part D premiums and ACA silver plan pricing both vary significantly by state and even by county, per our cms_medicare_plan_premiums dataset.
• Where you live relative to immigrant-population density. Census ACS data in our dataset shows states like Texas, California, and Florida carry disproportionately large foreign-born Medicare populations — meaning this H.R. 1 transition isn't a small-print edge case in those states, it's a mass event.
• Whether you'll ever re-qualify for Medicare. If there's any chance you regain eligibility later, documenting continuous creditable drug coverage during the gap is the single most important paperwork step you can take — it's the difference between a clean re-enrollment and a permanent monthly penalty. We walk through the enrollment-window mechanics in more depth in our guide to Medicare enrollment deadlines and Part B penalty math.

This isn't a policy story you can read once and file away. If it touches you or someone you're helping, the eligibility date, the formulary your specific drugs land on, and the premium your specific ZIP code sees are all things you need to check against your own numbers — not the averages in this post. That's exactly what Toravine is built to run for you before you're standing at that January 1 deadline with no time left to compare.

Data behind this post

The figures above are computed from the product's own reference tables, last refreshed 2026-09-20:

• 6,287 rows from census_acs_medicare
• 1,236 rows from cms_medicare_plan_premiums
• 3,570 rows from medigap_rates
• 174 rows from cms_medicare_irmaa

Sources

• As Health Insurance Costs Soar, Healthcare Workers Also Feel the Pinch — KFF Medicare
• Thousands of Immigrants Scheduled to Lose Medicare Coverage in the New Year — Medicare Rights Center
• Hackensack Meridian Health CEO to retire next year — Healthcare Dive
• Texas hospitals sue Independence Blue Cross over denied claims — Healthcare Dive
• New lawsuit targets Medicaid work requirements’ medical frailty rules — Healthcare Dive